- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03838549
Pre Pectoral Implant for Immediate Breast Reconstruction Using Single Port Endoscopy in Prophylactic Indication (MRIMOP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Gauthier Rathat, MD
- Phone Number: 0467336532
- Email: g-rathat@chu-montpellier.fr
Study Locations
-
-
Hérault
-
Montpellier, Hérault, France, 34295
- Recruiting
- Montpellier University Hospital
-
Contact:
- Gauthier Rathat, MD
- Phone Number: 0467336532
- Email: g.rathat@chu-montpellier.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with an indication for prophylactic uni or bilateral mastectomy (Genetic risk factors for breast cancer)
- Ask an immediate breast reconstruction during the surgery
- World Heath Organization score <3
- Glandular volume : french bra cup size A, B ou C
- Glandular ptosis <=2 (Classification and Algorithm for Treatment of Breast Ptosis)
- Contraception for woman of childbearing age and no pregnancy
- Valid Social Security
- Wrote consent
Exclusion Criteria:
- History of breast cancer surgery
- Breast cancer not operated on the side concerned by the prophylactic mastectomy
- Patient having had irradiant treatment
- Breast hypertrophy
- Smoking > 10 cigarette/day
- Body Mass Index > 30
- Large breast volume requiring prostheses > 500ml
- Chronic pulmonary obstructive gold 4
- ASA (Physical Status score of American Society of Anesthesiologists) > 3
- Chronic shoulder pain on the side to operate, or both shoulders
- History of abarticular pathology of the shoulder on the operating side
- Patient involvment in another clinical research
- Protected patient or unable to give consent
- Pregnant or breastfeeding woman
- Vulnerable person (Article L1121-6 of the Public Health Code)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: implant for breast reconstruction
20 patients female with genetic risk for breast cancer and who ask for prophylactic mastectomy.
They will have a prophylactic mastectomy with immediate breast reconstruction
|
It is an endoscopic approach for prophylactic mastectomy using an axillary single port
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
success rate of total mastectomy
Time Frame: one day
|
The total mastectomy is done by a scar in the axillary area, away from the breast, using single port endoscopy, with Implant base reconstruction in pre pectoral position. Complete excision of the gland by means of an incision on the axillary line, Installation of a definitive smooth prosthesis, Absence of conversion to a conventional approach, No skin necrosis |
one day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Operative time
Time Frame: one day
|
Duration of the prophylactic mastectomy with immediate breast reconstruction
|
one day
|
Open surgery conversion rate
Time Frame: one day
|
Open surgery conversion rate
|
one day
|
Number of participants with an infection
Time Frame: 1 and 3 months after the prophylactic mastectomy
|
Number of participants with early postoperative infection two months after the prophylactic mastectomy
|
1 and 3 months after the prophylactic mastectomy
|
Blood loss
Time Frame: one day
|
Blood loss (milliliters) during the prophylactic mastectomy with immediate breast reconstruction
|
one day
|
Number of participants with a local haematoma
Time Frame: Between the day of the prophylactic mastectomy and a month later
|
Number of participants with a local haematoma caused by the prophylactic mastectomy with immediate breast reconstruction
|
Between the day of the prophylactic mastectomy and a month later
|
Disunity of the scar
Time Frame: 1, 3, 6 and 12 months after the prophylactic mastectomy
|
Number of patients with disunity of the scar after the prophylactic mastectomy
|
1, 3, 6 and 12 months after the prophylactic mastectomy
|
Exposure of the prosthesis
Time Frame: 1, 3, 6 and 12 months after the prophylactic mastectomy
|
Number of patients with the prothesis exposed after the prophylactic mastectomy
|
1, 3, 6 and 12 months after the prophylactic mastectomy
|
Post-operative seromas after the prophylactic mastectomy
Time Frame: 1, 3, 6 and 12 months after the prophylactic mastectomy
|
Number of patients with seromas after the prophylactic mastectomy
|
1, 3, 6 and 12 months after the prophylactic mastectomy
|
Complication rate of subcutaneous insufflation
Time Frame: 3 and 12 months after the prophylactic mastectomy
|
Refractory induced hypercapnia: EtCO2 (expired fraction of CO2)> 45mmHg and refractory to ventilation ; second degree secondary burn
|
3 and 12 months after the prophylactic mastectomy
|
Skin case necrosis
Time Frame: 1, 3, 6 and 12 months after the prophylactic mastectomy
|
The presence of skin case necrosis will be noted during all the visits after the surgery.
It's severe if > 25%
|
1, 3, 6 and 12 months after the prophylactic mastectomy
|
Necrosis of areolo-nipple plaque
Time Frame: 1, 3, 6 and 12 months after the prophylactic mastectomy
|
The presence of necrosis of areolo-nipple plaque will be noted during all the visits after the surgery.
|
1, 3, 6 and 12 months after the prophylactic mastectomy
|
Analogue visual scale (EVA)
Time Frame: 1, 3, 6 and 12 months after the prophylactic mastectomy
|
The level of pain of the operated breasts will be self-assessed by the patient with EVA at 1, 3, 6, 12 months after the surgery.
EVA is mesured between 0 and 10 (0: no pain ; 10: extremely intense pain)
|
1, 3, 6 and 12 months after the prophylactic mastectomy
|
Hospital stay
Time Frame: Through discharge from hospitalization, an average of 7 days
|
The duration of hospitalization will be noted upon discharge from hospitalization
|
Through discharge from hospitalization, an average of 7 days
|
Aesthetic result
Time Frame: 3 and 12 months after the prophylactic mastectomy
|
BREAST-Q© questionnaire Version 2.0 measure the quality of life and satisfaction among patients undergoing breast surgery. This questionnaire includes 6 modules: 1) Augmentation module, 2) Reduction/Mastectomy module, 3) Breast cancer: a) Mastectomy module, b) Reconstruction module, c) Breast reconstruction expectations module, d) Breast conserving therapy module. The conceptual framework of the modules is comprised of following two overarching themes (or domains): 1) Health-related quality of life and 2) Patient satisfaction. 1) Under each of these domains, there are six subthemes; Quality of life: 1) Psychosocial, 2) Physical and 3) Sexual well-being; and Patient satisfaction: 4) Satisfaction with Breasts, 5) Satisfaction with Outcome and 6) Satisfaction with care. Cf. https://qportfolio.org/wp-content/uploads/2020/BREAST-Q-USERS-GUIDE-V2.pdf for the response options. |
3 and 12 months after the prophylactic mastectomy
|
Need for cosmetic reoperation
Time Frame: 3 and 12 months after the prophylactic mastectomy
|
the need to use one or more lipomodelages
|
3 and 12 months after the prophylactic mastectomy
|
Shoulder function
Time Frame: 3 months after the prophylactic mastectomy
|
Evaluation of the Constant score by a physiotherapist from the gynecology Department. The Constant score includes 5 items: Pain [0;5], Daily activity level [0;10], Level of work with the hand [0;10], Mobility [0;40] and Muscular force [0;25]. The Constant score is mesured between 0 and 100. The higher the score, the fewer problems there are for the patient, 100 is the ideal score. |
3 months after the prophylactic mastectomy
|
Life quality
Time Frame: 3 and 12 months after the prophylactic mastectomy
|
Quality of life with an european quality of life scale (EQ-5D-3L).
The EQ-5D-3L descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 3 levels: no problems, some problems, and extreme problems.
Rated level can be coded as a number 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3.
As a result, a person's health status can be defined by a 5-digit number, ranging from 11111 (having no problems in all dimensions) to 33333 (having extreme problems in all dimensions).
|
3 and 12 months after the prophylactic mastectomy
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RECHMPL18_0244
- UF 7672 (Other Identifier: UH Montpellier)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Prophylactic mastectomy with immediate breast reconstruction
-
University in Zielona GóraConvaTec Inc.UnknownBreast Cancer | Breast ReconstructionPoland
-
Institut Cancerologie de l'OuestCompleted
-
Karolinska University HospitalKarolinska Institutet; LifeCellCompletedBreast CancerSweden, United Kingdom
-
The Netherlands Cancer InstituteMaastricht University Medical Center; Erasmus Medical Center; Ziekenhuisgroep... and other collaboratorsEnrolling by invitationAutoimmune Diseases | Breast Cancer | Breast Implant; ComplicationsNetherlands
-
Odense University HospitalSykehuset Telemark; Sygehus LillebaeltUnknownBreast ReconstructionDenmark, Norway
-
University of MiamiActive, not recruitingBreast Cancer | Ductal CarcinomaUnited States
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
Case Comprehensive Cancer CenterWithdrawnBreast Cancer | Malignant Neoplasm of BreastUnited States
-
First Affiliated Hospital of Zhejiang UniversityUnknownBreast Reconstruction | Mammaplasty | BreastChina
-
Ottawa Hospital Research InstituteRecruitingBreast Cancer | MastectomyCanada